Journal of the American Podiatric Medical Association

95 KB

Open AccessArticle

1997 Diabetes Survey. Statistical Results

by Al Fisher Associates, Inc

J. Am. Podiatr. Med. Assoc. 1997, 87(12), 575-582; https://doi.org/10.7547/87507315-87-12-575 - 1 Dec 1997

Cited by 5 | Viewed by 50

This report presents the results of analyses of statistical data from 3,368 members of the American Podiatric Medical Association (APMA) who responded to the 1997 Diabetes Survey, conducted from February through March 1997. The purpose of the survey was to determine the extent [...] Read more.

► Show Figures

Figure 1

49 KB

Open AccessArticle

Possible Drug Interactions in Oral Treatment of Onychomycosis

by H. Irving Katz

J. Am. Podiatr. Med. Assoc. 1997, 87(12), 571-574; https://doi.org/10.7547/87507315-87-12-571 - 1 Dec 1997

Cited by 16 | Viewed by 111

Abstract

A variety of medications may interact with oral antifungal agents used to treat onychomycosis. This article summarizes some possible consequences of concurrent administration of various therapeutic agents with the oral antifungals fluconazole, griseofulvin, itraconazole, ketoconazole, and terbinafine. Full article

► Show Figures

Figure 1

57 KB

Open AccessArticle

Safety of Oral Terbinafine for Toenail Onychomycosis

by Richard Pollak and Stephan A. Billstein

J. Am. Podiatr. Med. Assoc. 1997, 87(12), 565-570; https://doi.org/10.7547/87507315-87-12-565 - 1 Dec 1997

Cited by 22 | Viewed by 215

Abstract

This open-label multicenter study evaluated the safety and efficacy of 12, 18, and 24 weeks of daily treatment with a 250-mg tablet of terbinafine for onychomycosis of the toenails. The safety data for 1,508 patients with a mean age of 50 years are reported here. Percentages below are based on this denominator. All patients received at least 12 weeks of therapy, with a possible addition of 6 or 12 weeks depending on disease extent. Patients were evaluated at baseline and at weeks 6, 12, 24, 30, 36, 48, and 72. Adverse events were reported in 674 (44.7%) patients; the events were considered unrelated to terbinafine in 557 (36.9%) patients and causally related or of uncertain relationship to terbinafine in 117 (7.8%) patients. Most events involved the skin, the gastrointestinal system, or the respiratory system. Statistically similar results were found for the elderly (over 60 years) and diabetic subpopulations. The study results confirm the safety of terbinafine in the population at large and show no differences for either the elderly or diabetic patients, who are at increased risk for onychomycosis and who frequently take concomitant medications with potential for drug interactions. Full article

537 KB

Open AccessArticle

Surgical Treatment of Mycotic Toenails

by Brian D. Mcinnes and Gary L. Dockery

J. Am. Podiatr. Med. Assoc. 1997, 87(12), 557-564; https://doi.org/10.7547/87507315-87-12-557 - 1 Dec 1997

Cited by 19 | Viewed by 57

Abstract

The authors present several options for the surgical treatment of painful and dystrophic mycotic toenails. The procedures include total and partial nail avulsion as well as chemical and excisional matrixectomies, both partial and total. Adjunctive treatment with topical and oral antifungal agents is [...] Read more.

► Show Figures

Figure 1

101 KB

Open AccessArticle

Traditional Approaches to Treatment of Onychomycosis

by Bryan C. Markinson, Sharon I. Monter and Glenn Cabrera

J. Am. Podiatr. Med. Assoc. 1997, 87(12), 551-556; https://doi.org/10.7547/87507315-87-12-551 - 1 Dec 1997

Cited by 14 | Viewed by 105

Abstract

The authors discuss the traditional approaches to treatment of onychomycosis in podiatric medicine: debridement, traditional oral agents, and topical medication. Although the newer systemic antifungal agents have proven to be both safe and effective, many podiatric physicians believe that for many patients, it [...] Read more.

► Show Figures

Figure 1

56 KB

Open AccessArticle

Epidemiology of Onychomycosis in Special-Risk Populations

by Leonard A. Levy

J. Am. Podiatr. Med. Assoc. 1997, 87(12), 546-550; https://doi.org/10.7547/87507315-87-12-546 - 1 Dec 1997

Cited by 91 | Viewed by 88

Abstract

A person’s susceptibility to onychomycosis and the course of the disease once the nails are infected are functions of the interaction of the fungal agent, the host, and environmental factors. The disease is reported to have an overall prevalence of 2% to 13%, but the prevalence is much higher in certain populations, such as older people and those with immunosuppressive conditions. Although onychomycosis may be merely a nuisance and an embarrassment for healthy individuals, some morbidity is seen with all population groups, but especially high-risk patients: diabetics, patients infected with human immunodeficiency virus (HIV), patients with acquired immunodeficiency syndrome (AIDS), and patients with other types of immunosuppression (eg, transplant recipients and patients on long-term corticosteroid therapy). Whether the increased prevalence of onychomycosis in the elderly (up to 30% by age 60) is related to changes in immune function is not known. Full article

► Show Figures

Figure 1

Journal Menu

Journal Browser

J. Am. Podiatr. Med. Assoc., Volume 87, Issue 12 (12 1997) – 6 articles , Pages 546-582

Further Information

Guidelines

MDPI Initiatives

Follow MDPI